Press coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a news impact score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.0971597567941 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- State Street Corp Buys 537739 Shares of Progenics Pharmaceuticals Inc. (PGNX) (iphonefresh.com)
- Progenics Pharmaceuticals Inc. (PGNX) Shares Gap Down After Earnings Miss (currenthollywood.com)
- Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- State Street Corp Buys 537739 Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) (vothemes.com)
- Average Price Target Of 12.67 Issued For Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) (wobko.net)
PGNX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “strong-buy” rating on shares of Progenics Pharmaceuticals in a report on Monday, April 24th. Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. ValuEngine lowered Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. TheStreet lowered Progenics Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 26th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $12.00 price objective on shares of Progenics Pharmaceuticals in a report on Thursday, June 8th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $12.33.
Progenics Pharmaceuticals (NASDAQ PGNX) traded up 5.63% during mid-day trading on Friday, reaching $5.63. The company’s stock had a trading volume of 1,622,633 shares. The firm’s market capitalization is $395.24 million. Progenics Pharmaceuticals has a 52 week low of $4.60 and a 52 week high of $11.72. The firm’s 50 day moving average price is $6.49 and its 200 day moving average price is $8.17.
Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.04. Progenics Pharmaceuticals had a negative net margin of 6.13% and a negative return on equity of 4.11%. The firm had revenue of $2.77 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. The company’s revenue was down 67.3% on a year-over-year basis. On average, analysts anticipate that Progenics Pharmaceuticals will post ($0.87) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by Rincon Hill News and is the sole property of of Rincon Hill News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://rinconhillneighbors.org/2017/08/13/progenics-pharmaceuticals-nasdaqpgnx-earning-somewhat-positive-news-coverage-study-shows-updated.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.